|
|
|
0 members (),
885
guests, and
25
robots. |
|
Key:
Admin,
Global Mod,
Mod
|
|
S |
M |
T |
W |
T |
F |
S |
|
|
|
1
|
2
|
3
|
4
|
5
|
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
|
20
|
21
|
22
|
23
|
24
|
25
|
26
|
|
27
|
28
|
29
|
30
|
31
|
|
|
|
There are no members with birthdays on this day. |
#478834
Sat 20 Oct 2018 02:33:PM
|
Joined: Feb 2001
Posts: 381,903
Launch Director
|
OP
Launch Director
Joined: Feb 2001
Posts: 381,903 |
An experimental cancer drug that Novartis hopes will raise the profile of its oncology portfolio cut the risk of death or disease progression by more than a third in breast cancer patients with a hard-to-target gene mutation.  Source: Novartis drug cut death risk by 35 percent in gene mutation breast cancer
David Cottle
UBB Owner & Administrator
|
|
CMS The Best Conveyancing solicitors conveyancing quotes throughout the UK
For any webhosting enquiries please email webmaster@aus-city.com
|
|
Forums60
Topics705,090
Posts739,704
Members2,957
| |
Most Online4,158
Jun 21st, 2024
|
|
|
|
|
Copyright 1996 - 2024 by David Cottle. Designed by David Bate Jr. All Rights Reserved.
By using this forum, the user agrees not to transfer any data or technical information received under the agreement, to any other entity without the express approval of the AUS-CITY Forum Admins and/or authors of individual posts (Forum Admins and DoD/USSPACECOM for the analysis of satellite tracking data).
Two-line elements (TLE) and all other satellite data presented and distributed via this forum and e-mail lists of AUS-CITY are distributed with permission from DoD/USSTRATCOM.
Reprise Hosting
|
|
